SecBot SecBot
8-K ·Filed Apr 21, 2026

OTLK

Outlook Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001104659-26-046014
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor for the FDA's formal decision in May 2026, which will determine the regulatory pathway and potential U.S. approval timeline for LYTENAVA™. Absent approval, the company may face delays in U.S. commercialization and revenue generation.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.2900
T+0 close · Apr 21, 2026 · via day close
Latest settled
+379.31%
T+60 · $1.39
Vs SPY
+374.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 22 $0.2900entry
  2. T+1 · 7mo ago −1.03%α −0.64% · $0.2870
  3. T+5 · 7mo ago −10.31%α −10.37% · $0.2601
  4. T+20 · 6mo ago −21.38%α −24.54% · $0.2280
  5. T+60 · 4mo ago +379.31%α +374.53% · $1.39
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Outlook Therapeutics completed a Federal Dispute Resolution (FDR) meeting with the FDA to appeal a Complete Response Letter (CRL) for its ONS-5010/ LYTENAVA™ biologics license application. A formal decision from the FDA is expected in May 2026.

Key Facts

  • Company held an FDR meeting with the FDA on April 21, 2026, to appeal a CRL issued on December 30, 2025, for ONS-5010/ LYTENAVA™.
  • The drug is under development for wet AMD and has already received marketing authorization in the EU and UK.
  • The company expects a formal decision from the FDA in May 2026.
  • No financial figures or material changes to operations were disclosed.

Financial Impact

No immediate financial impact disclosed; outcome depends on FDA's upcoming decision.

revenueregulatory approval timeline

Risk Factors

  • FDA may uphold the CRL, delaying or blocking U.S. approval.
  • Failure to gain U.S. approval could limit commercial potential and impact company valuation.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-046014
Document: tm2612353d1_ex99-1.htm0001104659-26-046014
Document: 0001104659-26-046014-index-headers.html0001104659-26-046014
Document: 0001104659-26-046014-index.html0001104659-26-046014
Document: 0001104659-26-046014.txt0001104659-26-046014

Track record

37 reports on OTLK

Performance horizon

13 of 23 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 23 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026